Formycon AG

General information
Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried, Bavaria
Germany

Contact person: Nicola Mikulcik, CBO
Company main phone: +49 (89) 864667100
Company main fax:  +49 (89) 864667110
Website:  https://www.formycon.com
Year founded:1999
Source of foundation:Independent foundation
No. of employees: Worldwide:  203
Corporate description / mission:
Formycon is a company that develops and manufactures biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases. The company's product FYB201 (Ranibizumab) is used in the treatment of various eye diseases in adults which cause damage to the retina, thereby impairing vision. The company's another product Ustekinumab is a human monoclonal antibody which targets the cytokines interleukin-12 and interleukin-23, is used for the treatment of several different serious inflammatory diseases, such as moderate to severe psoriasis.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2010
Remarks on ownership / listings
The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012.
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Anti-infectives
  • Antibodies
  • Biosimilars
  • Immunotherapy
  • Proteins
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:7
Phase I:1
Phase III:1
On the market:18
Description of products:
FYB201
FYB202
FYB203
FYB208, etc.
Financing details
Fiscal year (end of) 2025
Revenues:USD 52.11M
R&D expenses:USD 14.85M
Cash:USD 80.66M
No. of shares:17'672'927
Market cap. / valuation:USD 383.13M
© 2026 Biotechgate by Venture Valuation
X